Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 73.89% is 125% above its 5-year average of -294.29%, near the high end of its 5-year range (-71980.00%–95.50%).
1.00% above its 12-month average of 73.16%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 61.83%.
GROSS MARGIN
73.89%
GROSS MARGIN AVG TTM
73.16%
GROSS MARGIN AVG 3Y
55.01%
GROSS MARGIN AVG 5Y
-294.29%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+1.00%
CURRENT VS 3Y AVG
+34.31%
CURRENT VS 5Y AVG
+125.11%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.44%
median of 813 covered companies
CURRENT VS SECTOR MEDIAN
+82.72%
vs the sector median at left
ARS Pharmaceuticals, Inc.
Market Cap
$421.05M
Gross Margin
73.89%
TTM Avg
73.16%
3Y Avg
55.01%
5Y Avg
-294.29%
Market Cap
$417.72M
Gross Margin
44.71%
TTM Avg
23.54%
3Y Avg
19.38%
5Y Avg
-46.55%
Market Cap
$424.40M
Gross Margin
27.57%
TTM Avg
28.87%
3Y Avg
27.37%
5Y Avg
25.35%
Market Cap
$423.56M
Gross Margin
100.00%
TTM Avg
-208.30%
3Y Avg
-64.13%
5Y Avg
-41.74%
Market Cap
$412.22M
Gross Margin
68.83%
TTM Avg
69.91%
3Y Avg
69.67%
5Y Avg
69.68%
Market Cap
$429.12M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$409.36M
Gross Margin
61.77%
TTM Avg
80.89%
3Y Avg
90.44%
5Y Avg
-1369.52%
Market Cap
$432.32M
Gross Margin
42.92%
TTM Avg
41.39%
3Y Avg
40.24%
5Y Avg
40.24%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | $421.05M | 73.89% | 73.16% | 55.01% | -294.29% |
| Senseonics Holdings, Inc. (SENS)vs › | $417.72M | 44.71% | 23.54% | 19.38% | -46.55% |
| Tilray Brands, Inc. (TLRY)vs › | $424.40M | 27.57% | 28.87% | 27.37% | 25.35% |
| Editas Medicine, Inc. (EDIT)vs › | $423.56M | 100.00% | -208.30% | -64.13% | -41.74% |
| Myriad Genetics, Inc. (MYGN)vs › | $412.22M | 68.83% | 69.91% | 69.67% | 69.68% |
| Tectonic Therapeutic, Inc. (TECX)vs › | $429.12M | 0.00% | 0.00% | 0.00% | 0.00% |
| Prothena Corporation plc (PRTA)vs › | $409.36M | 61.77% | 80.89% | 90.44% | -1369.52% |
| NeoGenomics, Inc. (NEO)vs › | $432.32M | 42.92% | 41.39% | 40.24% | 40.24% |
| Rezolute, Inc. (RZLT)vs › | $407.80M | 0.00% | 0.00% | 0.00% | 0.00% |
| Strata Critical Medical, Inc. (SRTA)vs › | $409.28M | 20.56% | 22.27% | 19.63% | 19.86% |
Gross Margin
73.9%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 61.83% |
| 2026-03-31 | 72.29% |
| 2025-12-31 | 88.60% |
| 2025-09-30 | 74.80% |
| 2025-06-30 | 68.29% |
| 2025-03-31 | 49.25% |
| 2024-12-31 | 95.50% |
| 2024-09-30 | 94.58% |
| 2024-06-30 | -1279.20% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | -71980.00% |
| 2023-03-31 | -32160.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | -1906.88% |
| 2022-06-30 | -837.50% |
| 2022-03-31 | -717.95% |
| 2021-12-31 | -419.10% |
| 2021-09-30 | -870.08% |
| 2021-06-30 | -166.03% |
| 2021-03-31 | -166.03% |
| 2020-12-31 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
